PHILADELPHIA and VANCOUVER, British Columbia — August 6, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) has announced its board of directors’ approval of a share consolidation, where every ten pre-consolidation common shares will become one post-consolidation share.
The consolidation aims to maintain the company’s compliance with Nasdaq Capital Market listing requirements. Subject to approvals from the Toronto Stock Exchange (TSX) and Nasdaq, the consolidation is expected to take effect on August 25, 2025, with trading of the post-consolidation shares commencing around August 26, 2025. Fractional shares less than ½ will be canceled, while those at least ½ will be rounded up. Convertible securities will be adjusted accordingly.
Post-consolidation, the common shares are expected to continue trading on the TSX under the symbol “BCT” and on the Nasdaq under “BCTX”. Shareholders will receive instructions from Computershare Investor Services Inc. for exchanging their shares. Registered shareholders can also find a letter of transmittal on the company’s SEDAR+ profile. Beneficial holders should contact their intermediaries for processing details.
BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer care.
Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
Source: BriaCell Therapeutics Corp.
